Exelixis | EXEL - Current Assets

Stock Price
44.26
Daily Change
0.63 1.44%
Monthly
1.49%
Yearly
19.20%
Q1 Forecast
42.28

Exelixis reported $1.44B in Current Assets for its fiscal quarter ending in December of 2025.





Current Assets Change Date
Acadia Pharmaceuticals USD 1.08B 115.87M Sep/2025
Agios Pharmaceuticals USD 942.05M 91.06M Dec/2025
Akebia Therapeutics USD 258.34M 23.68M Sep/2025
Amgen USD 29.06B 1.17B Dec/2025
AstraZeneca USD 28.72B 1.22B Dec/2025
Bayer EUR 32.88B 873M Sep/2025
BioMarin Pharmaceutical USD 3.85B 49.21M Sep/2025
Bristol-Myers Squibb USD 35.63B 2.41B Sep/2025
Cytokinetics USD 977.35M 90.81M Sep/2025
Eisai JPY 840.88B 50.18B Dec/2025
Eli Lilly USD 55.63B 6.44B Dec/2025
Esperion Therapeutics USD 360.46M 17.87M Sep/2025
Exelixis USD 1.44B 41.03M Dec/2025
Genmab DKK 3.91B 127M Jun/2025
Glaxosmithkline GBP 23.98B 6.31B Sep/2025
Incyte USD 5.02B 746.01M Dec/2025
Ionis Pharmaceuticals USD 2.52B 58.16M Sep/2025
MacroGenics USD 232.09M 27.15M Sep/2025
Merck USD 47.56B 10.49B Sep/2025
Moderna USD 6.54B 54M Dec/2025
Nektar Therapeutics USD 281.36M 94.79M Sep/2025
Neurocrine Biosciences USD 2.52B 364.3M Dec/2025
Novartis USD 28.2B 2.26B Sep/2025
Pfizer USD 46.92B 3.22B Sep/2025
Puma Biotechnology USD 143.58M 7M Sep/2025
Sanofi EUR 30.95B 8.99B Dec/2025
Takeda JPY 3.12T 195.82B Dec/2025
Ultragenyx Pharmaceutical USD 643.21M 76.58M Sep/2025
Xencor USD 518.44M 5.29M Sep/2025